Novartis is a Swiss multinational pharma company, formed by the merger of Ciba-Geigy and Sandoz. Following the Sandoz (generics) spin-off in 2023, Novartis is now a focused innovative medicines company.
Oncology, Immunology, Cardiovascular, Neuroscience
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Entresto (sacubitril/valsartan) | Heart failure | $6.4B |
| Cosentyx (secukinumab) | Immunology | $5.0B |
| Kisqali (ribociclib) | Oncology (breast) | $2.1B |
| Tafinlar + Mekinist | Oncology (melanoma) | $1.7B |
| Leqvio (inclisiran) | Cardiology (lipids) | $0.4B |
| Pluvicto (lutetium Lu 177) | Oncology (prostate) | $0.4B |
Novartis is the #6 pharma company. Post-Sandoz spin-off, it is a pure-play innovative medicines company. Entresto and Cosentyx are the growth engines, with radioligand therapy (Pluvicto) as a novel modality.
Revenue projected to grow to $50B+ by 2026. Entresto remains a key growth driver (expanding to HFpEF). Pluvicto (radioligand) and Leqvio (siRNA) represent novel modality platforms with significant potential.
Novartis 2023 Annual Report. Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.